周颖
主任药师，副教授，博士生导师
研究领域：新药研发、临床试验及上市后临床研究
电话：（010）83575892
电子邮箱：zhouying0321@126.com
教育经历
北京大学理学博士（2025）
北京大学理学硕士（2006）
北京医科大学理学学士（1994）
工作经历
2026.5至今 北京大学第一医院临床试验中心副主任，联合党支部支部书记
2024.8至今 北京大学第一医院药剂科/药物临床试验机构联合党支部，支部书记
2023.12至今 北京大学第一医院药剂科，主任药师，主任
2023.6至今 北京大学第一医院药物临床试验机构，主任药师，副主任
2019.11-2023.12 北京大学第一医院药学部，主任药师，副主任
2011.09-2019.11 北京大学第一医院药剂科，主任药师，副主任
2010.08-2011.09 北京大学第一医院药剂科，主任药师
2004.12-2005.02 日本富山医科&药科大学药理学讲座，访问学者
社会兼职
国家卫健委抗菌药物临床应用与耐药评价专家委员会专业工作组专家
国家药品监督管理局药品审评中心审评专家
国家药品监督管理局 “药物警戒研究与评价重点实验室”学术委员
the FIP Policy Committee “Pharmacist's authority in pharmaceutical product selection: therapeutic interchange and substitution“ 成员
罕盟罕见病药物临床药学研究与应用分会主任委员
北京医师协会药学研究与转化分会主任委员
北京药学会临床研究与转化专委会主任委员
北京药理学会定量药理专委会主任委员
iPharma编委
《中国药房》副主编
《中国药物与临床》副主编
代表性论文（近一年）
1.Dan-Yun Ruan , Hao-Xiang Wu, Su-Xia Luo, Wen-Wen Huang ,Xin-Jun Liang, Zuo-Xing Niu, Qi Dang, Hong-Li Li, Zhan-Yu Pan, Hong-Xia Lu, Yan-Qiao Zhang 10 , Xing-Ya Li 11 , Xiu-Ying Xiao , Shi-Rong Cai , Yu-Gang Dong , Jian Zhang , Zhou Li , Hai-Tao Lan, Xin Wang , Ying Zhou, Lian Liu, He-Li Liu, Ping-Sheng Xu, Ai-Li Suo, Rui-Nuo Jia, Yong-Qiang Li, Xiao-Dong Peng, Si-Chen Wang , Ai-Ai Yu , Jie Xie , Miao-Zhen Qiu,*, Rui-Hua Xu*，The antibody-drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 triall; Nature Medicine 2025，31, 3037–3046 (Q1, IF=58.7)
2.Chen, Chaoyang; Niu, Zhenyu; Yang, Ting; Zhang, Xuanling; Wei, Ran; Pang, Xiaocong; Liu, Ran*; Zhou, Ying*. Evolution of Drug Development Trends in Multiple Sclerosis: Analysis of Mainland China and Global Landscapes From 2004 to 2024. CNS Neurosci Ther. 2026;32(4):e70870. （Q1，IF：5.0）
3.Hao, Wenyan; Sun, Nan; Xue, Ruifen; Chang, Junkai; Pang, Xiaocong*; Zhou, Ying*; Gao, Chunsheng*. Co-Delivery of Ferrostatin-1 and M2 Macrophage-Derived Exosomal Signals via Engineered Hybrid Nanovesicles Enables Synergistic Neuroprotection in Traumatic Brain Injury. ACS Appl Mater Interfaces. 2026;18(15):21791-21803（Q1，IF：8.2）
4.Ting Yang, Chaoyang Chen, Lingyue Ma, Ying Zhou*. Association of aggression and anti-seizure medications in pediatric patients: Disproportionality analysis using the FDA adverse event reporting system; European Journal of Pharmacology，2026;1011:178427 (Q1, IF=4.7)
5.Lili Lei, Junling Zhang, Ran Wei, Bingqi Dong, Xin Wang*,Ying Zhou*.Deciphering the Dual Role of Autophagy in Gastric Cancer and Gastroesophageal Junction Cancer: From Tumor Suppression to Cancer Progression;Discover Oncology:16(1), ( Q2,IF=2.8)
6.Liu, W.; Wu, L.; Rong, Z.; Zou, L.; Huang, Y.; Liu, W.; Li, C.; Liu, X.; Zhou, K.; Hu, K.; Huang, J.; Chen, C.; Sun, Q.; Zhou, Y.*; Dong, Y.*; Song, S.*; Pang, X*. Structure-Based Drug Design to Identify Potent, Selective, and Orally Available Cyclin-Dependent Kinase 9 Inhibitors for the Treatment of Castration-Resistant Prostate Cancer. J. Med. Chem. 2026,;69:11335–11364.
7.Zhang B, Song M, Wang Z, Zhou Y*, Pang X*. Use of failure mode and effects analysis for risk analysis of investigational drug products management in clinical trials. Am J Health Syst Pharm. 2026;83(12):677-90.
8.Liu W, Liu W, Rong Z, Song S, Zhou Y*, Pang X*. Therapeutic strategies for the fatty-acid-binding pocket of the spike protein: advances and perspectives. Drug Discov Today. 2026;31(3):104638.
9.Zhao S, Mu G, Liu X, Ma L, Yang L, Zhou Y. Pathophysiology, risk factors and clinical management for polymyxin-associated acute kidney injury. J Antimicrob Chemother. 2026;81(5):dkag132.
10.Wei Y#, Zhou Y#, Yu X, Gong L, Wang M, Feng X*. Comparative effectiveness of pharmacological treatments for fetal growth restriction: a network meta-analysis. Front Pharmacol. 2026;17:1792975.
11.Zhiqi Zhang, Zhuo Zhang, Qianxin Liu, Yan Zhang, Peng Jia, Lan Mi, Rui Lian, Fei Chen, Xiaocong Pang, Ying Zhou*. The impact of comprehensive pharmaceutical care on medication safety in gynecologic oncology chemotherapy patients. Exploratory Research in Clinical And Social Pharmacy. 2025;20:100681. （JCRQ3，IF=1.8）
12.Zhuo Zhang, Jiao Yu, Zhiqi Zhang, Qianxin Liu, Xiaocong Pang, Ying Zhou*. The Safety of Cadonilimab: A Systematic Review and Single-Arm Meta-Analysis, Cancer Medicine, 2025;14(17):e71210.（JCRQ2，IF=3.1）
13.Zhigang Li, Lixin Du, Binghua Du, Zia Ullah, Yinghe Zhang, Yanyang Tu*, Ying Zhou*,Bing Guo*.Inorganic and hybrid nanomaterials for NIR-II fluorescence imaging-guided therapy of Glioblastoma and perspectives. Theranostics 2025;15(12): 5616-5665. (Q1，IF=12.4)
14.Zhou Y, Long E, Shi T, Wang Z, Zhao J, Liu H, Lin Y, Jiang M, Lao H, Ge W, Cui Y*. External validation of vancomycin population pharmacokinetic models in ten cohort of Chinese infected patients. J Glob Antimicrob Resist 2022 Sep;30:163-172. (Q2, IF=4.035)
15.Pang X, Zhang J, He X, Gu Y, Qian BZ, Xie R, Yu W, Zhang X, Li T, Shi X*, Zhou Y*, Cui Y*. SPP1 Promotes Enzalutamide Resistance and Epithelial-Mesenchymal-Transition Activation in Castration-Resistant Prostate Cancer via PI3K/AKT and ERK1/2 Pathways. Oxid Med Cell Longev. 2021 Oct 22;2021:5806602. (Q2,IF=6.543)
16.Zhang E, Tian X, Li R, Chen C, Li M, Ma L, Wei R, Zhou Y*, Cui Y*. Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials. Orphanet J Rare Dis. 2021 Feb 15;16(1):87. (Q2, IF=4.123)
17.Daohuang Luo#, Ran Wei#, Xin Tian, Chaoyang Chen, Lingyun Ma, Min Li, Xiu Dong, Enyao Zhang, Ying Zhou*, Yimin Cui*. Efficacy and safety of azathioprine for neuromyelitis optica spectrum disorders: A meta-analysis of real-world studies. Mult Scler Relat Disord. 2020;46:102484.（Q2, IF=4.339）
18.Tian X, Chen C, Ma L, Wei R, Li M, Wang X, Wu Y, Zhou Y*, Cui Y*. Efficacy and safety of rituximab in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis. J Neuroimmunol. 2020 Oct 15;347:577317.（Q3, IF=3.478）
19.Li M, Ma L, Chen C, Lei L, Zhai X, Luo D, Zhou Y*, Cui Y*. Evaluation of Assays to Measure Aminoglycosides in Serum: Comparison of Accuracy and Precision Based on External Quality Assessment. Ther Drug Monit. 2020 Oct;42(5):710-715.（Q2, IF=3.681）
20.Lingyun Ma#, Daohuang Luo#, Ting Yang, Songtao Wu, Min Li, Chaoyang Chen, Shuang Zhou, Lingyue Ma, Ye Wu, Ying Zhou*, Yimin Cui*. Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies. BMC Endocr Disord. 2020;20(1):126. （Q3, IF=2.763）
21.Chen C-Y#, Li R-M#, Yang T, Ma L-Y, Zhou S, Li M, Zhou Y*, Cui Y-M*. Denosumab versus Zoledronic Acid in prevention of Skeletal-Related Events in Vulnerable cancer patients：A meta-analysis of randomized controlled trials. Clin Ther. 2020;42(8):1494-1507.e1.（Q2, IF=3.393）
22.Yang T#, Tian X#, Chen C-Y, Ma L-Y, Zhou S, Li M, Wu Y, Zhou Y*, Cui Y-M*. The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta-analysis. Br J Clin Pharmacol. 2020; 86(4): 637-645. 12.（Q1, IF=3.681）
23.Zhou H#, Zhou Y#，Ping Y, Tian S, Li G, Cui Y, Zheng B. The combination of loratadine with famotidine to relieve the symptoms of urinary frequency in female patients with bladder function disorders：First report of three cases. J Clin Pharm Ther. 2019 Oct; 44(5): 796-799.（Q3, IF=2.318）
24.Wang X, Han Y, Chen C, Ma L, Xiao H*, Zhou Y*, Cui Y, Wang F, Su B, Yao Y, Ding J. Population pharmacokinetics and dosage optimization of tacrolimus in pediatric patients with nephrotic syndrome. Int J Clin Pharmacol Ther. 2019; 57(3): 125-134. （JCRQ4, IF=1.265）
25.Zhou Y, Gao F, Chen C, Ma L, Yang T, Liu X, Liu Y, Wang X, Zhao X, Que C, Li S, Lv J, Cui Y*, Yang L*. Development of a Population Pharmacokinetic Model of Vancomycin and its Application in Chinese Geriatric Patients with Pulmonary Infections. Eur J Drug Metab Pharmacokinet. 2019 Jun; 44(3): 361-370. （JCRQ4, IF=1.9）
26.Li M#, Zhou Y#, Chen C, Yang T, Zhou S, Chen S, Wu Y, Cui Y*. Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis. Orphanet J Rare Dis. 2019; 14(1): 39. （JCRQ2, IF=3.987）
27.Chen CY#, Zhou Y#, Cui YM*, Yang T, Zhao X, Wu Y. Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy. J Clin Pharm Ther. 2019; 44(2): 300-311.（JCRQ3, IF=2.138）
28.Yang T#, Zhou Y#, Chen C, Lu M, Ma L, Cui Y*. Genotype-guided dosing versus conventional dosing of warfarin: A meta-analysis of 15 randomized controlled trials. J Clin Pharm Ther. 2019; 44(2): 197-208.（JCRQ3, IF=2.138）
荣誉奖励
1.2025年5月北京科协“创新争先活动”奖
2.2021年11月获全国药学专业学位研究生教育指导委员会颁发的“第五届全国药学专业学位优秀教学案例奖”
3.2019年中华医学科技奖三等奖外周组织微创病理在神经系统罕见病诊断中的临床研究及推广应用，2020年2月
4.2018年度北京大学医学部重大项目组织奖，2019年3月
5.2013年获得华夏医学科技奖三等奖：新药临床试验药物基因组学技术平台建立
6.2012年中国药学会科技技术奖二等奖：新药临床试验药物基因组学技术平台建立